

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 17 (2007) 2470-2473

## Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents

Masahiro Ikejiri,<sup>a</sup> Masayuki Saijo,<sup>b</sup> Shigeru Morikawa,<sup>b</sup> Shuetsu Fukushi,<sup>b</sup> Tetsuya Mizutani,<sup>b</sup> Ichiro Kurane<sup>b</sup> and Tokumi Maruyama<sup>a,\*</sup>

<sup>a</sup>Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University, 1314-1 Shido, Sanuki, Kagawa 769-2193, Japan <sup>b</sup>Special Pathogens Laboratory, Department of Virology 1, National Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

> Received 12 December 2006; revised 22 January 2007; accepted 9 February 2007 Available online 13 February 2007

Abstract—Nucleoside analogues that have 6-chloropurine as the nucleobase were synthesized and evaluated for anti-SARS-CoV activity by plaque reduction and yield reduction assays in order to develop novel anti-SARS-CoV agents. Among these analogues, two compounds, namely, 1 and 11, exhibited promising anti-SARS-CoV activity that was comparable to those of mizoribine and ribavirin, which are known anti-SARS-CoV agents. Moreover, we observed several SAR trends such as the antiviral effects of the 6-chloropurine moiety, unprotected 5'-hydroxyl group and benzoylated 5'-hydroxyl group. © 2007 Elsevier Ltd. All rights reserved.

Severe acute respiratory syndrome (SARS) is an emerging infectious disease of the 21st century and poses a global threat to public health, mainly leading to fatal infection with influenza-like symptoms such as high fever, dry cough, pneumonia and dyspnoea.<sup>1</sup> This disease appeared in the Guandong province of southern China in late 2002, and subsequently spread to 29 countries in early 2003, affecting approximately 8000 persons. The overall mortality rate of SARS has amounted to approximately 10%. Following the identification of the causative pathogen—a new coronavirus (CoV) named SARS-CoV—in 2003, several compounds have been reported to exhibit antiviral activity against SARS-CoV.<sup>2</sup> However, thus far, no effective treatment has been developed.

In our previous studies, several nucleoside derivatives having 6-chloropurine as the nucleobase showed potent antiviral activity against some types of viruses.<sup>3</sup> We presume that the 6-chloropurine moiety could play an important role in the antiviral activity; in fact, several 6-chloropurine analogues are known to inhibit bacterial RNA polymerases.<sup>4</sup> Therefore, we expected that nucleoside analogues that have 6-chloropurine would be efficacious against SARS-CoV. Thus, several nucleoside analogues, namely, 1–11, which could be readily prepared or are commercially available, were designed as anti-SARS-CoV agents (Fig. 1). In this report, we



Figure 1. Structures of the nucleoside analogues.

Keywords: SARS-CoV; Nucleoside; 6-Chloropurine; Antiviral.

<sup>\*</sup> Corresponding author. E-mail: maruyama@kph.bunri-u.ac.jp

<sup>0960-894</sup>X/\$ - see front matter @ 2007 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmcl.2007.02.026

describe the syntheses and anti-SARS-CoV activities of the nucleoside analogues 1–11.

Compounds 1, 4 and 5 were purchased from chemical companies, and 3, 7 and 11 were prepared according to previous literatures.<sup>5</sup> Syntheses of the (deoxy)ribonucleoside derivatives 2 and 6 are illustrated in Scheme 1. Regioselective protection of the 2',3'-diol moiety of 1 vielded acetonide 12,6 which was subsequently benzoylated to afford 13 with a 91% yield over two steps. Cleavage of the acetonide group produced the desired product 2 with a 61% yield. Acetvlation of both hydroxyl groups of 2'-deoxyadenosine afforded 14,7 which was transformed to 6-chloropurine 15 with a 57% yield over two steps. The deprotection of the acetyl groups was accomplished at ice-water temperature to avoid decomposition of the 6-chloropurine moiety, thereby producing the desired product 6 with a 76% yield. Syntheses of the acvelic analogues 8 and 9 and the carbocvelic oxetanocin analogue 10 are outlined in Scheme 2. The Mitsunobu reaction of known alcohol 16<sup>8</sup> with 6-chloropurine, followed by the removal of the acetonide group in 17, resulted in the desired diol 8 with a 66%vield over two steps. Subsequently, monobenzoylation of 8 was carried out via hydrolysis of the corresponding orthobenzoate<sup>9</sup> to afford the desired benzoate  $\hat{9}$  with a 67% yield. Triol 18, which was prepared as described in a previous literature,<sup>10</sup> was converted to bis-silyl ether 19; this compound was then subjected to a Mitsunobu reaction to yield the 6-chloropurine derivative 20. Finally, cleavage of the TBS groups produced the desired product10 with a 96% yield. We could not directly convert benzoate  $11^{5c}$  to 10 because of the instability of the 6-chloropurine moiety under basic conditions.



Scheme 1. Reagents and conditions: (a)  $Me_2C(OMe)_2$ , *p*-TsOH, acetone, rt, 4 h, 91%; (b) BzCl, Et<sub>3</sub>N, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to rt, 2 h, quant; (c) AcOH/water (4:1), 60 °C, 5 h, 61%; (d) Ac<sub>2</sub>O, DMAP, Pyr, 4 h; (e) *t*-BuONO, Et<sub>4</sub>NCl, CCl<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to 50 °C, 4.5 h, 57% from 2'-deoxyadenosine; (f) 2 M NH<sub>3</sub>–MeOH, 0 °C, 9 h, 76%.



Scheme 2. Reagents and conditions: (a) 6-Chloropurine, PPh<sub>3</sub>, 1, 1'-azobis(N,N-dimethylformamide), THF, rt, 2 days; (b) p-TsOH, MeOH, rt, 24 h, 66% from 16; (c) PhC(OMe)<sub>3</sub>, p-TsOH, MeCN, rt, 4 h, followed by water, rt, 3 h, 67%; (d) TBSCl, Pyr, -20 °C to rt, 18 h, 37%; (e) 6-chloropurine, PPh<sub>3</sub>, 1,1'-azobis(N,N-dimethylformamide), THF, rt to 45 °C, 18 h, 44% (recovery of 19, 40%); (f) p-TsOH, MeOH, rt, 18 h, 96%.

The antiviral effect of the prepared nucleoside analogues was evaluated by a plaque reduction assay and a yield reduction assay with SARS-CoV Frankfurt-1 strain in Vero E6 cells as described in a previreport.<sup>11</sup> The anti-SARS-CoV ous activities determined by the plaque reduction assay are shown in Figure 2 and Table 1. Compounds 1 and 11 showed potent activity (IC<sub>50</sub>: 48.7  $\mu$ M and 14.5  $\mu$ M, respectively), and compound 2 showed weak activity (IC<sub>50</sub>: 108  $\mu$ M), while the other analogues 3–10 did not show any significant activity (IC<sub>50</sub> > 300  $\mu$ M). Notably, the inhibitory activities of compounds 1 and 11 against SARS-CoV were comparable to those of mizoribine and ribavirin, which were reported as potential anti-SARS-CoV agents by our group,<sup>11</sup> although the antiviral indices of 1 and 11 were smaller than those of mizoribine and ribavirin. Figure 3 illustrates the anti-SARS-CoV activities of 1, 2, and 11 determined by the yield reduction assay. The inhibitory effect of 1 was the greatest among the three compounds; the virus yield at a concentration of approximately 20 µM decreased to one-hundredth or less of the control (Fig. 3, left). It is important to note that this inhibitory effect was superior to those of



Figure 2. Inhibitory effect of compounds 1, 2 and 11 on plaque formation of SARS-CoV Frankfurt-1 strain in the plaque reduction assay.

Table 1. Inhibitory and cytotoxic concentrations of nucleoside analogues 1, 2, 3–10 and 11; ribavirin; and mizoribine in the plaque reduction  $assay^a$ 

Compound	$IC_{50}\left(\mu M\right)^{b}$	$CC_{50} \left(\mu M\right)^c$	Antiviral index <sup>d</sup>
1	48.7	279	5.7
2	108	174	1.6
3–10	>300	_	
11	14.5	78	5.4
Ribavirin <sup>e</sup>	82	>850	>10
Mizoribine <sup>e</sup>	13.5	>700	>52

<sup>a</sup> The same experiment was performed at least three times independently with SARS-CoV Frankfurt-1 strain and Vero E6 cells.

<sup>b</sup> Average of 50% inhibitory concentrations or concentration required to reduce virus plaque formation by 50%.

<sup>c</sup> Average of 50% cytotoxic concentrations (CC) or concentration required to reduce cell growth by 50%. The CC was measured using the WST-1 cytotoxicity assay kit.

 $^{\rm d}$  Antiviral index was defined as the 50% toxic dose divided by the 50% inhibitory dose.

<sup>e</sup> Extracts obtained from a previous study.<sup>11</sup>

mizoribine and ribavirin since approximately 35  $\mu$ M of mizoribine or 200  $\mu$ M of ribavirin was required to decrease the virus yield to one-tenth of the control.<sup>11</sup> In the case of compounds **2** and **11**, approximately 50–70  $\mu$ M of each compound was required to reduce the virus yield to one-hundredth of the control (Fig. 3, middle and right).

These results revealed several structure-activity relationship (SAR) trends. A chlorine atom at the 6-position of the purine base was considered to be important for the anti-SARS-CoV activity (compound 1 vs 3 and 4); however, an introduction of the amino group at the 2-position of 6-chloropurine, which corresponds to a guanine derivative, was unfavourable for the antiviral activity (compound 5). Although the reason for this trend is unclear, there is a possibility that due to its electrophilic nature,<sup>12</sup> the 6-chloropurine moiety can form a covalent bond with the target enzyme and can induce an effective irreversible inhibition.<sup>13</sup> The substitution of weak leaving groups (e.g., – OMe (compound 3) or –SMe (compound 4)) for the chlorine atom at the 6-position that led to the diminu-

tion of the antiviral activity also supports this possibility. In the case of ribofuranosyl structure, unprotected 5'-hydroxyl group was important in the antiviral effect (compound 1 vs 2); this would indicate that following the intracellular phosphorylation of the 5'-hydroxyl group to the corresponding triphosphates, compound 1 exhibited antiviral activity in the same manner as common nucleoside antivirals.<sup>14</sup> The type of sugar moiety also influenced the anti-SARS-CoV activity. For example, the 2'-deoxy- and 3'-deoxyribonucleoside derivatives 6 and 7 showed weak antiviral activity as compared to the ribonucleoside derivative 1. The conversion to an acyclic backbone that imitates the antiviral agent penciclovir (i.e., 9-[4-Hydroxy-3-(hydroxymethyl)butyl]guanine) also decreased the activity (compound 1 vs 8 and 9). Interestingly, the carbocyclic oxetanocin analogue 11 whose hydroxyl group was protected by benzoylation exhibited potential activity as compared to unprotected 10 that exhibited almost no activity.<sup>15</sup> This trend seems to be different from those of the common nucleoside antivirals (including compound 1), and could indicate that compound 11 acts on SARS-CoV through another pathway that does not involve the intracellular phosphorylation.

In conclusion, we have synthesized several nucleoside analogues having 6-chloropurine as the nucleobase. Among these analogues, two compounds, namely, 1 and 11, were found to be efficacious against SARS-CoV and showed antiviral activities comparable to those of mizoribine and ribavirin. This study revealed several curious SAR trends such as the antiviral effects of the 6-chloropurine moiety (compounds 1 and 11), unprotected 5'-hydroxyl group (compound 1), and protected (benzoylated) 5'-hydroxyl group (compound 11). Although some issues such as reduction of cytotoxicity remain to be resolved, we hope that the results of the present study will contribute to further development of antiviral agents against SARS-CoV. Studies that focus on further optimisation of the synthesized compounds and their biological evaluation will be reported in due course.



Figure 3. Inhibitory effect of nucleoside analogues 1, 2 and 11 in the yield reduction assay. The same experiment was performed at least three times independently with SARS-CoV Frankfurt-1 strain and Vero E6 cells.

## Acknowledgement

This research was partially supported by a Grant-in-Aid for Young Scientists (B), No. 18790093, from the Japan Society for the Promotion of Science (JSPS).

## **References and notes**

- Recent reviews on SARS-CoV, see for example: (a) De Clercq, E. Expert Rev. Anti Infect. Ther 2006, 4, 291; (b) Tsunetsugu-Yokota, Y.; Ohnishi, K.; Takemori, T. Rev. Med. Virol. 2006, 16, 117; (c) De Haan, C. A.; Rottier, P. J. Cell Microbiol. 2006, 8, 1211; (d) Hsueh, P.-R.; Yang, P.-C. J. Microbiol. Immunol. Infect. 2005, 38, 82; (e) Bartlam, M.; Yang, H.; Rao, Z. Curr. Opin. Struct. Biol. 2005, 15, 664.
- For example: Cho, J. H.; Bernard, D. L.; Sidwell, R. W.; Kern, E. R.; Chu, C. K. J. Med. Chem. 2006, 49, 1140; Zhang, H.-Z.; Zhang, H.; Kemnitzer, W.; Tseng, B.; Cinatl, J., Jr.; Michaelis, M.; Doerr, H. W.; Cai, S. X. J. Med. Chem. 2006, 49, 1198; Yang, S.; Chen, S.-J.; Hsu, M.-F.; Wu, J.-D.; Tseng, C.-T. K.; Liu, Y.-F.; Chen, H.-C.; Kuo, C.-W.; Wu, C.-S.; Chang, L.-W.; Chen, W.-C.; Liao, S.-Y.; Chang, T.-Y.; Hung, H.-H.; Shr, H.-L.; Liu, C.-Y.; Huang, Y.-A.; Chang, L.-Y.; Hsu, J.-C.; Peters, C. J.; Wang, A. H.-J.; Hsu, M.-C. J. Med. Chem. 2006, 49, 4971; Hoever, G.; Baltina, L.; Michaelis, M.; Kondratenko, R.; Baltina, L.; Tolstikov, G. A.; Doerr, H. W., ; Cinatl, J., Jr. J. Med. Chem. 2005, 48, 1256, and also see Ref. 1a and references therein.
- Maruyama, T.; Sato, Y.; Oto, Y.; Takahashi, Y.; Snoeck, R.; Andrei, G.; Witvrouw, M.; De Clercq, E. *Chem. Pharm. Bull.* **1996**, *44*, 2331; Honjo, M.; Maruyama, T.; Horikawa, M.; Balzarini, J.; De Clercq, E. *Chem. Pharm. Bull.* **1987**, *35*, 3227.
- Ruddon, R. W.; Rainey, C. H.; Zedeck, M. S. FEBS Lett. 1970, 7, 119.
- Compound 3: (a) Samano, V.; Miles, R. W.; Robins, M. J. J. Am. Chem. Soc. 1994, 116, 9331; Compound 7: (b) Takamatsu, S.; Maruyama, T.; Katayama, S.; Hirose, N.; Naito, M.; Izawa, K. J. Org. Chem. 2001, 66, 7469; Compound 11: (c) Sato, Y.; Ueyama, K.; Maruyama, T.; Richman, D. D. Nucleosides Nucleotides 1996, 15, 109.
- 6. Kappler, F.; Hampton, A. J. Med. Chem. 1990, 33, 2545.

- van der Wenden, E. M.; von Frijtag Drabbe Künzel, J. K.; Mathôt, R. A. A.; Danhof, M.; IJzerman, A. P.; Soudijn, W. J. Med. Chem. 1995, 38, 4000.
- Harnden, M. R.; Jarvest, R. L.; Bacon, T. H.; Boyd, M. R. J. Med. Chem. 1987, 30, 1636.
- 9. Ikejiri, M.; Miyashita, K.; Tsunemi, T.; Imanishi, T. *Tetrahedron Lett.* 2004, 45, 1243.
- A racemic mixture of 26 was employed. Maruyama, T.; Hanai, Y.; Sato, Y.; Snoeck, R.; Andrei, G.; Hosoya, M.; Balzarini, J.; De Clercq, E. *Chem. Pharm. Bull.* 1993, 41, 516.
- Saijo, M.; Morikawa, S.; Fukushi, S.; Mizutani, T.; Hasegawa, H.; Nagata, N.; Iwata, N.; Kurane, I. Antiviral Res. 2005, 66, 159.
- The 6-chloropurine moiety reacts with various nucleophiles (e.g., -NH, -OH, -SH) under mild conditions. For example: Gao, Z.-G.; Duong, H. T.; Sonina, T.; Kim, S.-K.; Rompaey, P. V.; Calenbergh, S. V.; Mamedova, L.; Kim, M. J.; Kim, A. Y.; Liang, B. T.; Jeong, L. S.; Jacobsen, K. A. J. Med. Chem. 2006, 49, 2689; Caamaño, O.; Gómez, G.; Fernández, F.; García, M. D.; García-Mera, X.; De Clercq, E. Synthesis 2004, 2855; Yadav, V.; Chu, C. K.; Rais, R. H.; Safarjalani, O. N. A.; Guarcello, V.; Naguib, F. N. M.; el Kouni, M. H. J. Med. Chem. 2004, 47, 1987.
- Zedeck and coworkers have referred to the irreversible binding of 6-halogenated purine nucleuses in their report (Ref. 4). Reviews on irreversible inhibitors, see for example: Silverman, R. B. *Methods Enzymol.* **1995**, *259*, 240; Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E. *Chem. Rev.* **2002**, *102*, 4639.
- Arimilli, M. N.; Dougherty, J. P.; Cundy, K. C.; Bischofberger, N. In *Advances in Antiviral Drug Design*; De Clercq, E., Ed.; Jai Press: Stamford Connecticut, 1999; Vol. 3, pp 69–91.
- Lobucavir, [1*R*-(1α,2β,3α)]-9-[2,3- bis(hydroxymethyl)cyclobutyl]guanine, is known to inhibit some types of viruses after the intracellular phosphorylation Tenney, D. J.; Yamanaka, G.; Voss, S. M.; Cianci, C. W.; Tuomari, A. V.; Sheaffer, A. K.; Alam, M.; Colonno, R. J. *Antimicrob. Agents Chemother.* 1997, 41, 2680, Therefore, compound 10, an analogue of lobucavir, might be similarly phosphorylated. However, the phosphorylated derivative showed almost no antiviral activity, probably because of low affinity to SARS-CoV.